TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05228249
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05228249
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05228249
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05542849
Drug: Acarbose Tablets 50mg
Normalized name: acarbose Oral Tablet
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose is an Alpha-glucosidase inhibitor. It is a compound also known under the names Glucobay, Precose, and Prandase. Acarbose is used (with diet and other medications) to treat type 2 diabetes (condition in which the body does not use~insulin normally and therefore cannot control the amount of sugar in the blood). Acarbose works by blocking α- glucosidase, which breaks down starch (aka amylose) into glucose (sugar) into your blood. Slowing food digestion~helps keep blood glucose from rising very high after meals.
Study: NCT04590781
Drug: XmAb18087 ± Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: XmAb18087 ± Pembrolizumab
Study: NCT05903339
Drug: Alum 500 mcg
Normalized name: alum
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (500 mcg)
Study: NCT05903339
Drug: V3G CH848 mRNA-Tr2 50mcg
Normalized name: mRNA-3705
DrugBank: mRNA-3705 (DB17668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (50 mcg)
Study: NCT04475276
Drug: Alphalipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle modification with Alphalipoic acid for 12 weeks
Study: NCT04282239
Drug: Ropivacaine 0.5% Injectable Solution
Normalized name: ROPivacaine 0.5% injectable solution
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 mL on each side of anterior chest for a total of 30mL
Study: NCT04282239
Drug: Dexmedetomidine 0.004 MG/ML
Normalized name: dexmedetomidine 0.004 MG/ML
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mL
Study: NCT05521022
Drug: AT-02
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT-02 via IV infusion
Study: NCT04832971
Drug: ARO-ANG3
Normalized name: ARO-ANG3
DrugBank: ARO-ANG3 (DB17626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARO-ANG3 Injection
Study: NCT00002228
Drug: Enfuvirtide
Normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05582109
Drug: Envafolimab, Lenvatinib Combined With TACE
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PD-L1 inhibitor
Study: NCT04768296
Drug: Berzosertib
Normalized name: Berzosertib
DrugBank: Berzosertib (DB11794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received Berzosertib at a dose of 105 milligrams per square meter (mg/m\^2 ) intravenously on Day 2 and Day 5 of each 21-day cycle until disease progression or other criteria for study intervention discontinuation are met.
Study: NCT04768296
Drug: Berzosertib
Normalized name: Berzosertib
DrugBank: Berzosertib (DB11794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received Berzosertib at a dose of 210 mg/m\^2 intravenously on Day 2 and Day 5 of each 21-day cycle in DL2 of safety run-in part and main part until disease progression or other criteria for study intervention discontinuation are met.
Study: NCT04768296
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received Topotecan at a dose of 1.25 mg/m\^2 intravenously on Days 1 through 5 of each 21-day cycle in DL1 and DL2 of safety run-in part and main part until disease progression or other criteria for study intervention discontinuation are met.
Study: NCT06677788
Drug: Roflumilast 500 Mcg Oral Tablet
Normalized name: roflumilast 500 mcg oral tablet
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients in this group received roflumilast 500 μg once daily for three months.
Study: NCT06677788
Drug: Vitamin E capsule
Normalized name: Vitamin E Capsule
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vitamin E group or control group (n=24) which received vitamin E 1000 mg once daily
Study: NCT04522804
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin is a classic psychedelic of medium duration that is well-tolerated and has a documented safety and efficacy record that makes it uniquely well-suited to the existential issues that arise in this patient population. Psilocybin has been described as an 'existential medicine' given patient testimonials as to its acute and lasting effects on interpersonal connection, ability to more deeply engage with meaningful activities and relationships, dramatic reductions in fear of death, and a renewed sense of well-being.
Study: NCT06394661
Drug: Serplulimab+NabPE
Normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serplulimab plus neoadjuvant nab-PE: Epirubicin 75mg/m2 ivgtt on Day 1+Albumin Paclitaxel 260mg/m2 ivgtt on Day 1+Serplulimab 4.5mg/Kg ivgtt on Day 3）
Study: NCT04689360
Drug: elamipretide
Normalized name: Elamipretide
DrugBank: Elamipretide (DB11981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elamipretide is an aromatic-cationic tetrapeptide that readily penetrates cell membranes and transiently localizes to the inner mitochondrial membrane.
Study: NCT04747795
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV
Study: NCT05923866
Drug: ONO-2808
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of ONO-2808 at low, middle or high doses once a daily for 24 weeks
Study: NCT05546242
Drug: Cabotegravir/Rilpivirine
Normalized name: CABOTEGRAVIR/RILPIVIRINE
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: injectable long-acting cabotegravir 600mg + long-acting rilpivirine 900mg administered every 2 months
Study: NCT06678230
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alibulin 1.4mg/m2, D1, 8; Every 3 weeks is a cycle; Androtinib 12mg, QD, po, applied for 14 days, stopped for 7 days, and every 3 weeks was a cycle.
Study: NCT05752552
Drug: DO-2
Normalized name: Marlido-25 Kit
DrugBank: 5-Iodo-2'-Deoxyuridine-5'-Monophosphate (DB02324)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deuterated MET kinase inhibitor
Study: NCT06679673
Drug: SHR-1701
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1701
Study: NCT06679673
Drug: BP102
Normalized name: Buprenorphine/Naloxone
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BP102
Study: NCT05981703
Drug: BGB-26808
Normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Planned doses administered orally as a tablet daily.
Study: NCT05981703
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Planned doses administered by intravenous infusion.
Study: NCT06598514
Drug: Chlorhexidine
Normalized name: Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will use a 2% chlorhexidine perineal lavage following defecation
Study: NCT06598514
Drug: Sterile Water
Normalized name: sterile water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will use a sterile water perineal lavage following defecation
Study: NCT06605131
Drug: GP+Toripalimab+CCRT
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Induction Chemotherapy (GP Regimen combined with Toripalimab):~1. GP Regimen Gemcitabine: 1000 mg/m² on Day 1 and Day 8; Cisplatin (DDP): 80 mg/m² on Day 1-3; every 3 weeks for 3 cycles.~2. Toripalimab: For patients weighing ≥ 40 kg: 240 mg on Day 1; For patients weighing less than 40 kg: 3 mg/kg; every 3 weeks for 3 cycles.~2. Concurrent Chemoradiotherapy (CCRT): Cisplatin (DDP): 100 mg/m², starting on the first day of radiotherapy; every 3 weeks for 3 cycles
Study: NCT05683860
Drug: WVE-004
Normalized name: WVE 003
DrugBank: WVE-003 (DB17870)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WVE-004 is a stereopure antisense oligonucleotide. It is administered via intrathecal injection
Study: NCT06149091
Drug: Tranexamic Acid；
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) is an antifibrinolytic drug that competitively inhibits the activation of plasminogen. After its efficacy and safety were confirmed in several randomized controlled trials, both systemic and topical administration of TXA have been widely used for hemostasis in trauma and various surgical settings.
Study: NCT06149091
Drug: Adrenalin
Normalized name: Adrenalin
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In diagnostic bronchoscopy, one of the most commonly used topical hemostatic agent is epinephrine. The primary mechanism of epinephrine is vasoconstriction, leading to reduced blood flow and hemostasis.
Study: NCT06602232
Drug: DR-01
Normalized name: DR-01
DrugBank: DR-01 (DB18258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DR-01 will be administered via IV infusion.
Study: NCT00002244
Drug: WF10
Normalized name: Sodium hypochlorite
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05918341
Drug: Piracetam
Normalized name: Piracetam
DrugBank: Piracetam (DB09210)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subtherapeutic dose of piracetam (once-weekly doses of 7.5 mg, 5 mg, 2.5 mg and 1.25 mg)
Study: NCT05703841
Drug: JNJ-77242113
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-77242113 will be administered orally as an immediate-release (IR) file-coated tablet.
Study: NCT05321875
Drug: Candesartan
Normalized name: Candesartan
DrugBank: Candesartan (DB13919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 years treatment with candesartan target dose: 32 mg or maximum tolerated dose after dose escalation from 16 mg
Study: NCT05094596
Drug: Montelukast sodium 10 mg treatment
Normalized name: montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group 2 (n=60) received 10 mg/day oral montelukast in addition to standard treatment
Study: NCT05094596
Drug: Montelukast sodium 20 mg treatment
Normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group 3 (n=60) were given 20 mg/day oral montelukast in addition to standard treatment.
Study: NCT05103657
Drug: BI 1358894
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1358894
Study: NCT05103917
Drug: X4P-001
Normalized name: CXCR4 INHIBITOR X4P-001
DrugBank: Mavorixafor (DB05501)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CXCR4 inhibitor
Study: NCT06616441
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group (A) only will receive intra-peritoneal 40 ml bupivacaine 0.2%, after laparoscopic procedure before removing trocars.
Study: NCT06395844
Drug: METR-NK cell(Metabolic Remodeling Nature Killer Cells)
Normalized name: Hongo Killer
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The minimum amount of METR-NK cells infused each time should be no less than 7.5×10\^7 cells, Continuous infusion for 2 days constitutes one course, with 4 courses. The infusion is given every 2 weeks.
Study: NCT04845841
Drug: Elinzanetant (BAY3427080) treatment A
Normalized name: Hongo Killer Treatment
DrugBank: Elinzanetant (DB18968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT04845841
Drug: Elinzanetant (BAY3427080) treatment B
Normalized name: Elinzanetant
DrugBank: Elinzanetant (DB18968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT03123029
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax will be administered orally.
Study: NCT00000953
Drug: Sorivudine
Normalized name: Sorivudine
DrugBank: Sorivudine (DB11998)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000953
Drug: Acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05528679
Drug: 610 100mg
Normalized name: petrolatum 610 MG/ML
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg administered subcutaneously Q4W
Study: NCT05049668
Drug: ATGAM plus CsA with or without Eltrombopag
Normalized name: ATGAM
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Standard treatment with or without Eltrombopag
Study: NCT05229055
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: giving ketamine intranasal
Study: NCT06678555
Drug: Lorlatinib
Normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lorlatinib is an ALK/ROS1 tyrosin kinase inhibitor.
Study: NCT05528679
Drug: 610 300mg
Normalized name: petrolatum 610 MG/ML
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg administered subcutaneously Q4W
Study: NCT04963608
Drug: Inetetamab
Normalized name: Inetetamab
DrugBank: Inetetamab (DB17457)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days
Study: NCT00001108
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00001108
Drug: Nelfinavir mesylate
Normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06608940
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab, intravenous, 1500 mg, every 4 weeks, continuous
Study: NCT06608940
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab, intravenous, 300 mg, 1 dose on Cycle 1 Day 1
Study: NCT00001108
Drug: Saquinavir
Normalized name: Saquinavir
DrugBank: Saquinavir (DB01232)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001108
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001108
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00001108
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001108
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01004315
Drug: Tolterodine
Normalized name: Tolterodine
DrugBank: Tolterodine (DB01036)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05472896
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the dosage of epirubicin was determined according to the tumor size, and the maximum dose was limited to 40 mg. The volume ratio of lipiodol to epirubicin aqueous solution was 2:1. The volume of lipiodol used was calculated by the size and vascularity of the tumor, within 20 mL.
Study: NCT06531642
Drug: Protonix (Pantoprazole) 40 mg q 12 hrs for 2 days
Normalized name: pantoprazole 40 MG [Protonix]
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Within 2 hours of ED admission after inclusion criteria is met, administer 1st dose of Protonix (pantoprazole) 40mg, then followed by 40mg q12hrs for 2 additional days.
Study: NCT06531642
Drug: Protonix (pantoprazole) 40 mg q 24 hrs for 2 days
Normalized name: pantoprazole 40 MG [Protonix]
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administer 1st dose of 40mg Protonix (pantoprazole) at the usual timing (current practice: in the intensive care unit), then followed by 40mg daily for 2 additional days.
Study: NCT05467202
Drug: CLL1 CAR-T
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single infusion of autologous CLL1 CAR-T cells administered intravenously
Study: NCT05274191
Drug: Pyrotinib Maleate
Normalized name: maleate
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib ± standard regimen Pyrotinib: 400 mg/day (once a day, orally at the same time every day), continued until disease progression;
Study: NCT05050981
Drug: Hormone replacement therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy: menopause hormone therapy with estrogen-only or oestrogen-progestin.
Study: NCT05050981
Drug: Selective serotonin reuptake inhibitors
Normalized name: Selective serotonin reuptake inhibitors
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors: anyone in the category, e.g.: fluoxetine, sertraline, etc.
Study: NCT04167618
Drug: 177Lu-DTPA-omburtamab
Normalized name: DTPA
DrugBank: Omburtamab (DB15635)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological, radiolabeled DPTA-omburtamab
Study: NCT06015022
Drug: Epigallocatechin gallate (EGCG)
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG is a green tea-derived catechin
Study: NCT05690035
Drug: Tislelizumab & Fruquintinib
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: combinational treatment of Tislelizumab and Fruquintinib until PD, intolerable toxicity, death or withdrawal of informed consent
Study: NCT06679569
Drug: rocuronium 0.6 mg/kg/hr continuous infusion
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To maintain Train-of-four count 0 during surgery: Administration of continuous infusion of rocuronium at a rate of 0.6 mg/kg/hr to achieve and sustain deep neuromuscular blockade.
Study: NCT05371639
Drug: Tian Ma Bian Chun Zhi Gan Tablets
Normalized name: Zhi ma oil
DrugBank: Sesame oil (DB11172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tian Ma Bian Chun Zhi Gan Tablets, 0.1g per pill which contains 14mg Tian Ma Bian Chun Zhi Gan, 3 pills per time, 2 times per day for 36 weeks.
Study: NCT05884255
Drug: Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lutetium (177Lu) Oxodotreotide Injection combined with standard-dose long-acting Octreotide
Study: NCT05884255
Drug: long-acting Octreotide.
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: High-dose long-acting Octreotide.
Study: NCT05312476
Drug: Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets
Normalized name: Autologous bi-epitope BCMA-targeted CAR T-cells
DrugBank: Ciltacabtagene autoleucel (DB16738)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Dose escalation studies:3 dose groups in total: expect 3-6 cases in each group, and dose set at 1×106/kg，3×106/kg，6×106/kg.~2. Dose extension study:3 cases (1 dose group).
Study: NCT05202288
Drug: Inmazeb
Normalized name: Inmazeb
DrugBank: Atoltivimab (DB15898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of Inmazeb
Study: NCT06677827
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: External Oblique Intercostal plane block technique with 20 ml bupivacaine 0.25% only bilateral
Study: NCT06677827
Drug: Magnesium Sulfate and Bupivacaine 0.125%
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: External Oblique Intercostal plane block technique with 20 ml bupivacaine 0.25%+200 mg magnesium sulphate bilateral
Study: NCT04913025
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 60-minute IV infusion, as a flat dose of 480mg
Study: NCT04913025
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 60-minute IV infusion, as a flat dose of 400mg
Study: NCT06085079
Drug: Ixekizumab Prefilled Syringe
Normalized name: ixekizumab Prefilled Syringe
DrugBank: Ixekizumab (DB11569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ixekizumab is a humanized IgG4 monoclonal antibody that binds with high affinity and specificity to IL-17A. This medication is currently approved for the treatment of plaque Ps, ankylosing spondylitis, and psoriatic arthritis.
Study: NCT05429489
Drug: Intravenous morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous morphine 0.1 mg/kg
Study: NCT05305131
Drug: cisplatin and gemcitabine
Normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2
Study: NCT05305131
Drug: induction chemotherapy cisplatin, gemcitabine, bevacizumab and pembrolizumab.
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Day -7 (+/-1 day): IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2+ IV pembrolizumab 200mg over 30 minutes Day 8: IV Gemcitabine 1000mg/m2 Day 15 (for cycles 1 and 2 only): IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes
Study: NCT05886257
Drug: Candonilimab
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg/kg, iv.drip, every 3 week
Study: NCT05886257
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15mg/kg, iv.drip, every 3 week
Study: NCT05997940
Drug: PENG block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The PENG block was performed with the patient in the supine position at preoperative waiting room. A curvilinear low-frequency ultrasound probe (2-5 MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22 gauge, 100 mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic solution was injected in 5 mL increments while observing for adequate fluid spread in this plane for a total volume of 20 mL